For Parkinson Therapy IPX203, Amneal has announced the complete response resubmission.

Published Date: 11 Feb 2024

Results from the phase 3 RISE-PD trial, in which treated patients demonstrated greater ON time than immediate-release CD/LD, supported the new drug application for IPX203, a novel oral formulation of carbidopa/levodopa.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

4.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

5.

Virtual Reality Travel Reduces Cancer Pain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot